A number of research firms have changed their ratings and price targets for Vanda Pharmaceuticals (NASDAQ: VNDA):

  • 8/8/2017 – Vanda Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “strong-buy” rating. They now have a $18.00 price target on the stock. According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “
  • 8/3/2017 – Vanda Pharmaceuticals was given a new $18.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 8/3/2017 – Vanda Pharmaceuticals was given a new $23.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 8/3/2017 – Vanda Pharmaceuticals was given a new $21.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 7/18/2017 – Vanda Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong sell” rating. According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “
  • 6/27/2017 – Vanda Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $23.00 price target on the stock.
  • 6/14/2017 – Vanda Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) opened at 15.50 on Wednesday. Vanda Pharmaceuticals Inc. has a 1-year low of $11.58 and a 1-year high of $18.00. The firm’s market cap is $693.13 million. The company’s 50 day moving average price is $16.07 and its 200-day moving average price is $14.63.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.18. The firm had revenue of $42.06 million for the quarter, compared to analyst estimates of $40.31 million. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. Vanda Pharmaceuticals’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.01 earnings per share. Equities analysts expect that Vanda Pharmaceuticals Inc. will post ($0.61) EPS for the current fiscal year.

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Receive News & Ratings for Vanda Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.